Pediatric GLP-1
Wegovy is the first GLP-1 FDA-approved for adolescents with obesity (age 12+, BMI ≥95th percentile). This hub covers eligibility, family-conversation prep, and the open questions clinicians still flag.
Wegovy is approved for adolescents 12+ with BMI at or above the 95th percentile for age/sex (CDC growth charts). Zepbound is not yet approved for pediatric use. Tirzepatide adolescent trials are ongoing. Most pediatricians require documentation of prior lifestyle-intervention attempt and family engagement.
Pediatric obesity carries stigma; the conversation matters. Frame it as treating a chronic disease, not a willpower failure. Involve the adolescent in the decision. Pediatric obesity medicine specialists report higher long-term adherence when the teen agrees with the plan, not just the parent.
Long-term safety data in growing bodies is the biggest unknown. The STEP TEENS trial was 68 weeks; what happens over 5-10 years is genuinely unclear. Bone density, growth velocity, and pubertal timing are being monitored in registry studies. The American Academy of Pediatrics 2023 obesity guideline supports pharmacotherapy at 12+ with appropriate monitoring.
Wegovy is FDA-approved for adolescents 12+ with BMI at or above the 95th percentile for age and sex (per CDC growth charts). Some prescribers extend to the 85th percentile in the presence of weight-related comorbidities; that is closer to off-label and varies by clinic.
It is debated. The American Academy of Pediatrics 2023 guideline endorses pharmacotherapy from age 12 for obesity. Critics flag long-term safety unknowns and the medicalization of normal childhood. The right answer depends on the individual teen, BMI trajectory, comorbidities, and family values.
Comparison includes consultation flow, formulary, and pricing.
See top-rated providers